The ASTER 70s study, promoted by Unicancer and Institut Curie, demonstrates that the addition of chemotherapy to hormone therapy does not significantly improve survival in women aged 70 and over with hormone-sensitive breast cancer at high genomic risk. These results, published in the The Lancet journal, represent a major advance forward towards more personalized care tailored to the age and frailty of patients.